PD-1(T) TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC

PURPOSE: Durable clinical benefit to PD-1 blockade in non–small cell lung cancer (NSCLC) is currently limited to a small fraction of patients, underlining the need for predictive biomarkers. We recently identified a tumor-reactive tumor-infiltrating T lymphocyte (TIL) pool, termed PD-1(T) TILs, with...

Descripción completa

Detalles Bibliográficos
Autores principales: Hummelink, Karlijn, van der Noort, Vincent, Muller, Mirte, Schouten, Robert D., Lalezari, Ferry, Peters, Dennis, Theelen, Willemijn S.M.E., Koelzer, Viktor H., Mertz, Kirsten D., Zippelius, Alfred, van den Heuvel, Michel M., Broeks, Annegien, Haanen, John B.A.G., Schumacher, Ton N., Meijer, Gerrit A., Smit, Egbert F., Monkhorst, Kim, Thommen, Daniela S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Precision Medicine and Imaging
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762332/
https://www.ncbi.nlm.nih.gov/pubmed/35852792
http://dx.doi.org/10.1158/1078-0432.CCR-22-0992

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762332/
https://www.ncbi.nlm.nih.gov/pubmed/35852792
http://dx.doi.org/10.1158/1078-0432.CCR-22-0992

Ejemplares similares